Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this is when the “B” word starts getting thrown around
Maybe he supports family in another country
Raising money for 3-4 months isn’t going to last forever.
It must be filed by Tuesday.
In Germany they seem to swing between unbridled optimism and unbridled despair even more so than in the States.
I had my broker contact NP directly about it.
Summing it up...CYDY had a deadline to meet with Samsung. CYDY and Samsung have an extremely good relationship. NP exercised his warrants/options (cashless to him) to bring CYDY current. NON DILUTIVE TO SHAREHOLDERS.
This will allow CYDY and Samsung to move forward with production that is at it's highest demand ever.
Here's a simple scenario?- You order 50 of a product and it's time to pay but you have new orders of 500,000 and climbing every day. Well pay for that 50 on time.. and quickly... then the relationship builds as your order books rise.
Chump
Crazy anti-vaxxer, always my first source of scientific information.
1. How come no one noticed or observed that it is a RANTES disease? How come everyone missed such a big thing?
2. Virus in plasma - again how come we never heard it from all the big pharma and scientist working in all countries? This should have been clear?
Is it that Dr BP has come to a conclusion that is not true?
They say in the article that the researchers did not know results when they made the change but they knew how many had died in total and they therefore knew their endpoint (deaths) wasn’t going to be “statistically significant” so it appears they really did know.
NIAID said in response to questions Thursday that it made the switch eight weeks later to the more limited measure of “time to recovery'' based on modeling that took into account new information about the course of the disease. The initial measurement period of two weeks, it said, was deemed to be too short as scientists learned more about the lengthy time patients could be seriously ill with covid-19, NIAID said.
Form 144 is not for an exercise of warrants or options it's for a proposed sale of shares. A form 4 details insider warrant or option exercise.
If a form 4 isn't filed with the SEC by Monday then that 144 is false.
From what I can see Jefferies LLC has never had a prior business transaction with either Nader Pourhassan or Cytodyn.
There's been no dump so your speculation is unfounded.
This is much more interesting.
https://www.sec.gov/comments/s7-08-08/s70808-318.pdf
I thought you were referring to form 144, which is what I was referencing.
Where's the link then?
The form 144 is fake, here's why. Aggregate value of shares divided by number of shares is $3.25. It is based on a share price that existed on the date specified, in this case April 30th. The share price on April 30th was between $3.46-$3.70.
I think it's not a huge deal if it is true.
who are the main financial investors in UNITAID....none other than George Soros, Bill & Melinda Gates, and WHO
What bad news? Registration of unregistered shares and warrant exercise is to be expected with a rise in share price. The sooner we get rid of the overhang the happier I'll be.
You seem to be missing the fact that Cytodyn needs one year of operating capital.
Publication tomorrow is only on the New York patients. The other publication in a few weeks should cover the non-New York patients where survival is currently 100%.
in any new offering
The Chinese study showed that remdesivir lowered viral load no better than placebo. The results released tomorrow should include viral load levels that will back up Dr. Patterson's claim. Do you think Dr. Patterson would make that claim without proof?
RANTES or CCL5 is a good target for treatment. It is expressed in 100 diseases. If Lero can positively impact CCL5 then it can adddress many more diseases.
Fauci stated clearly he wants a cocktail
Do we know if CYDY has any lobbyists
his discovery of RANTES or CCL5 and not IL6 being the cause of the deaths is really new finding
Who needs their liver unless they have some fava beans and a nice Chianti.
The outcomes will be anecdotal. The results from the IncellDX tests that support the MOA will not be.
Why hasn't the NIH released the actual data for remdesivir?
Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059)
Leronlimab covers all of the indications that Humira covers (and more). Humira is the best selling drug in the world - $19.9 billion.
Large doses of famotidine can cause breathing problems and heart arrhythmia.
Just what is needed with a virus that causes breathing problems already.
With heart problems you have famotidine combined with hydroxychloroquine both of which cause heart problems combined with a virus that causes heart problems.
Are those doctors trying to kill off patients so they don't have to deal with them.
COVID-19 is spreading via the RANTES
Due diligence is your friend. Instead of asking questions find the answers yourself. But just to give you a little education.
At the time of both filings I believe Cytodyn still had a laboratory in Florida.
CytoDyn Veterinary Medicine LLC filed as a corporation in 2011 as a corporation under former President Kenneth Van Ness as a subsidiary to test and possibly market Cytofeline.
Advanced Genetic Technologies, Inc filed as a corporation in 2006 under former President Allen D. Allen, unkown why.
The store owners said that NP had told them they were made by Native Americans, then they recanted. Not uncommon for people facing felonies to turn federal witness by making false claims.
In stroke prevention you wouldn't need full continuous coverage as you would with HIV or in cases of severe reactions like a cytokine storm or GVHD. Best guess would be every two weeks, 350mg but that time may be able to be stretched out further. For treatment after a stroke it would probably be once a week, 700mg for maximum effect and going over to a stroke prevention regimen.
Taking leronlimab for one indication of course would have protective effects against the wide spectrum of indications. For instance quite a while back I had mentioned using leronlimab as a prophylaxis for those who had previously had cancer or were genetically predisposed to having cancer. I've read stories of women who had breast cancer running in the family who had their breasts surgically removed. Leronlimab may make that unnecessary.
A Native American tribe filed a complaint because the stores were misrepresenting them as being made by Native Americans.
allegedly
From 2010, May 15 Progenics - 324mg dose (no longer used) - Even at that low dose, good results. Not currently used weekly so no washout.
SC PRO 140 demonstrated potent and prolonged antiretroviral activity. Mean log10 reductions in HIV-1 RNA were 0.23, 0.99 (p=0.0093), 1.37 (p=0.0001), and 1.65 (p<0.0001) for the placebo, 162mg weekly, 324mg biweekly and 324mg weekly dose groups, respectively. Viral loads remained suppressed between successive doses. Treatment was generally well tolerated.
Screening samples from the three subjects with dual/mixed virus were analyzed post-study using the ES Trofile assay. One subject had detectable levels of dual/mixed virus pre-treatment and would have been excluded from the study if ES Trofile had been available for screening. Dual/mixed virus was first detected on Day 15 or Day 29 in the other two subjects. Studies are ongoing to determine if these subjects had pre-existing dual/mixed virus at levels below the ES Trofile’s limit of detection. Both subjects had only R5 virus detected in ES Trofile at end of study.
A loading dose may decrease the potential for dual/mixed virus to emerge following initiation of treatment with PRO 140, as may the presence of additional antiretroviral agents in future combination regimens. Lastly, since the potential for outgrowth of CXCR4-using viruses is related to the sensitivity of the tropism test used for screening, this resistance pathway may diminish in clinical importance as tropism assays become increasingly sensitive in detecting CXCR4-using viruses.
The PRO 140 results are especially notable in that monotherapy was followed by slow washout of drug. Such conditions can foster development of antiretroviral drug resistance (36;37). Overall, our findings suggest that PRO 140 presents a high barrier to resistance.